» Articles » PMID: 16420083

Variables Associated with Alcohol, Drug, and Daily Smoking Cessation in Patients with Severe Mental Illnesses

Overview
Specialty Psychiatry
Date 2006 Jan 20
PMID 16420083
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Co-occurrence of substance use disorders and severe mental illnesses (SMIs) is a major U.S. public health issue, although the role of tobacco is usually neglected. This study explored variables associated with alcohol, drug, and smoking cessation in a naturalistic setting.

Method: Logistic regression was used to study variables associated with cessation of alcohol and drug use disorder and daily smoking in 560 SMI inpatients and outpatients from central Kentucky facilities. Patients with a lifetime history of alcohol or drug use disorder were considered to be in cessation if they had not suffered from abuse or dependence during the last year. Alcohol and drug use disorder diagnoses were determined using the Clinician Rating of Alcohol and Drug Use Disorder. Patients were recruited from July 2000 to March 2003.

Results: The cessation rates for alcohol and drug use disorders were, respectively, 44% (95% CI = 39% to 49%) and 46% (CI = 40% to 51%); these were higher than the daily cigarette smoking cessation rate of 10% (CI = 7% to 13%). Drug use disorders (p < or = .02), outpatient status (p < .001), and having a medical complication of obesity (diabetes mellitus, hypertension, or hyperlipidemia; p < .001) were significantly associated with alcohol cessation. Alcohol use disorder (p < .001), starting treatment with psychiatric medications after 33 years of age (p < .001), taking these medications for 14 years or more (p = .02), schizophrenia diagnosis (p < .001), outpatient status (p = .03), and obesity (p = .04) were significantly associated with drug cessation. Cessation of daily smoking was associated with hypertension (p = .02), late start of treatment with psychiatric medications (> 33 years old; p = .01), and lack of lifetime drug abuse (p < .001).

Conclusions: These results are limited by the cross-sectional and naturalistic design but suggest that public health experts, researchers, and clinicians need to mindfully address smoking cessation in patients with SMIs. Clinicians may want to consider that medical illnesses may motivate patients with SMIs to stop substance abuse and that patients with SMIs who abuse both alcohol and drugs rarely stop abusing just one of them.

Citing Articles

Smoking Addiction in Patients with Schizophrenia Spectrum Disorders and Its Perception and Intervention in Healthcare Personnel Assigned to Psycho-Rehabilitation Programs: A Qualitative Research.

Caponnetto P, Maglia M, Mangione M, Vergopia C, Prezzavento G, Polosa R Healthcare (Basel). 2022; 10(11).

PMID: 36421599 PMC: 9690727. DOI: 10.3390/healthcare10112275.


The Relationship between 10 Years Risk of Cardiovascular Disease and Schizophrenia Symptoms: Preliminary Results.

Kilicaslan E, Karakilic M, Erol A Psychiatry Investig. 2019; 16(12):933-939.

PMID: 31801314 PMC: 6933131. DOI: 10.30773/pi.2019.0063.


ADGRL3 (LPHN3) variants predict substance use disorder.

Arcos-Burgos M, Velez J, Martinez A, Ribases M, Ramos-Quiroga J, Sanchez-Mora C Transl Psychiatry. 2019; 9(1):42.

PMID: 30696812 PMC: 6351584. DOI: 10.1038/s41398-019-0396-7.


Impact of Cannabis Use on Long-Term Remission in Bipolar I and Schizoaffective Disorder.

Kim S, Dodd S, Berk L, Kulkarni J, de Castella A, Fitzgerald P Psychiatry Investig. 2015; 12(3):349-55.

PMID: 26207128 PMC: 4504917. DOI: 10.4306/pi.2015.12.3.349.


Clinical characteristics of heavy and non-heavy smokers with schizophrenia.

Wehring H, Liu F, McMahon R, Mackowick K, Love R, Dixon L Schizophr Res. 2012; 138(2-3):285-9.

PMID: 22578720 PMC: 4062915. DOI: 10.1016/j.schres.2012.03.024.